Regeneron donates ebola treatment for use in countries at risk of outbreaks

Regeneron (REGN) Pharmaceuticals will donate up to 500 doses of Inmazeb, an Ebola treatment for the infection caused by Orthoebolavirus zairense, to the World Health Organization for exclusive use by governments of low- and lower-middle income countries. The donation ensures this life-saving treatment continues to be available and free for people living in countries most at risk for Ebola outbreaks, and follows Regeneron’s delivery of an Inmazeb stockpile to the U.S. Government as part of the U.S. Department of Health and Human Services efforts to enhance national preparedness for public health emergencies. Alongside the WHO supply agreement, Regeneron is rushing Inmazeb treatments to the Democratic Republic of the Congo for use in the current outbreak. Since 2018, Regeneron has worked with public health agencies and non-governmental organizations to rapidly offer Inmazeb at no cost under a compassionate use protocol to any country experiencing an Orthoebolavirus zairense outbreak, including the DRC and Guinea. Through June 2025, 266 patients have received treatment.